玻璃体腔注射阿柏西普预防糖尿病视网膜病变视力威胁并发症的Protocol W随机试验四年视力结局
该随机临床试验在美国和加拿大64个中心纳入328例(399眼)中度至重度非增殖性糖尿病视网膜病变(NPDR)且无中心受累糖尿病黄斑水肿(CI-DME)的成人患者,比较玻璃体腔注射阿柏西普2.0 mg与假注射的4年视力结局。结果显示,阿柏西普组4年发生增殖性糖尿病视网膜病变(PDR)或伴视力下降的CI-DME的累积概率为33.9%,假注射组为56.9%(校正HR 0.40,97.5% CI 0.28-0.57;P<.001),但两组视力变化无显著差异(校正均数差-0.5字母,97.5% CI -2.3至1.3;P=.52)。作者认为,作为预防策略,阿柏西普可能不普遍适用于无CI-DME的NPDR患者。
要点
- 阿柏西普组4年发生PDR或伴视力下降的CI-DME的累积概率为33.9%,假注射组为56.9%(校正HR 0.40;P<.001)。
- 4年视力变化:阿柏西普组平均-2.7字母,假注射组平均-2.4字母,校正均数差-0.5字母(P=.52),无显著差异。
- 作者认为,作为预防策略,阿柏西普可能不普遍适用于无CI-DME的NPDR患者。
核心结论
- 在中度至重度NPDR且无CI-DME的患者中,4年时与假注射相比,仅在出现视力威胁并发症时才启动阿柏西普治疗,结果获得统计学显著的解剖学改善,但视力无改善。
- 作者认为,作为本试验中所用的预防策略,阿柏西普可能不普遍适用于无CI-DME的NPDR患者。
研究设计与样本
- 随机临床试验,在美国和加拿大64个临床中心于2016年1月至2018年3月开展,纳入328例成人(399眼)中度至重度NPDR(ETDRS严重程度43-53级;范围0最差至100最佳)且无CI-DME。
- 眼随机分配至阿柏西普2.0 mg组(n=200)或假注射组(n=199);2年内按既定间隔注射8次,之后每季度注射至4年,除非眼改善至轻度NPDR或更好;两组均在高风险PDR或伴视力下降的CI-DME发生时给予阿柏西普治疗。
主要发现
- 4年发生PDR或伴视力下降的CI-DME的累积概率:阿柏西普组33.9% vs 假注射组56.9%(校正HR 0.40,97.5% CI 0.28-0.57;P<.001)。
- 基线至4年视力(最佳矫正ETDRS字母评分)平均(SD)变化:阿柏西普组-2.7(6.5)字母 vs 假注射组-2.4(5.8)字母(校正均数差-0.5字母,97.5% CI -2.3至1.3;P=.52)。
- 抗血小板试验协作组心血管/脑血管事件率:双侧参与者9.9%(7/71),单侧阿柏西普参与者10.9%(14/129),单侧假注射参与者7.8%(10/128)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Anti-vascular endothelial growth factor (VEGF) injections in eyes with nonproliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME) reduce development of vision-threatening complications from diabetes over at least 2 years, but whether this treatment has a longer-term benefit on visual acuity is unknown. OBJECTIVE: To compare the primary 4-year outcomes of visual acuity and rates of vision-threatening complications in eyes with moderate to severe NPDR treated with intravitreal aflibercept compared with sham. The primary 2-year analysis of this study has been reported. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted at 64 clinical sites in the US and Canada from January 2016 to March 2018, enrolling 328 adults (399 eyes) with moderate to severe NPDR (Early Treatment Diabetic Retinopathy Study [ETDRS] severity level 43-53; range, 0 [worst] to 100 [best]) without CI-DME. INTERVENTIONS: Eyes were randomly assigned to 2.0 mg aflibercept (n = 200) or sham (n = 199). Eight injections were administered at defined intervals through 2 years, continuing quarterly through 4 years unless the eye improved to mild NPDR or better. Aflibercept was given in both groups to treat development of high-risk proliferative diabetic retinopathy (PDR) or CI-DME with vision loss. MAIN OUTCOMES AND MEASURES: Development of PDR or CI-DME with vision loss (≥10 letters at 1 visit or ≥5 letters at 2 consecutive visits) and change in visual acuity (best corrected ETDRS letter score) from baseline to 4 years. RESULTS: Among participants (mean age 56 years; 42.4% female; 5% Asian, 15% Black, 32% Hispanic, 45% White), the 4-year cumulative probability of developing PDR or CI-DME with vision loss was 33.9% with aflibercept vs 56.9% with sham (adjusted hazard ratio, 0.40 [97.5% CI, 0.28 to 0.57]; P < .001). The mean (SD) change in visual acuity from baseline to 4 years was -2.7 (6.5) letters with aflibercept and -2.4 (5.8) letters with sham (adjusted mean difference, -0.5 letters [97.5% CI, -2.3 to 1.3]; P = .52). Antiplatelet Trialists' Collaboration cardiovascular/cerebrovascular event rates were 9.9% (7 of 71) in bilateral participants, 10.9% (14 of 129) in unilateral aflibercept participants, and 7.8% (10 of 128) in unilateral sham participants. CONCLUSIONS AND RELEVANCE: Among patients with NPDR but without CI-DME at 4 years treatment with aflibercept vs sham, initiating aflibercept treatment only if vision-threatening complications developed, resulted in statistically significant anatomic improvement but no improvement in visual acuity. Aflibercept as a preventive strategy, as used in this trial, may not be generally warranted for patients with NPDR without CI-DME. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02634333.
引用
- Maturi RK, Glassman AR, Josic K, et al. Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy. JAMA. 2023. PMID: 36749332. doi:10.1001/jama.2022.25029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。